» Articles » PMID: 22182677

"Electro-clinical Syndromes" with Onset in Paediatric Age: the Highlights of the Clinical-EEG, Genetic and Therapeutic Advances

Overview
Journal Ital J Pediatr
Publisher Biomed Central
Specialty Pediatrics
Date 2011 Dec 21
PMID 22182677
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The genetic causes underlying epilepsy remain largely unknown, and the impact of available genetic data on the nosology of epilepsy is still limited. Thus, at present, classification of epileptic disorders should be mainly based on electroclinical features. Electro-clinical syndrome is a term used to identify a group of clinical entities showing a cluster of electro-clinical characteristics, with signs and symptoms that together define a distinctive, recognizable, clinical disorder. These often become the focus of treatment trials as well as of genetic, neuropsychological, and neuroimaging investigations. They are distinctive disorders identifiable on the basis of a typical age onset, specific EEG characteristics, seizure types, and often other features which, when taken together, permit a specific diagnosis which, in turn, often has implications for treatment, management, and prognosis. Each electro-clinical syndrome can be classified according to age at onset, cognitive and developmental antecedents and consequences, motor and sensory examinations, EEG features, provoking or triggering factors, and patterns of seizure occurrence with respect to sleep. Therefore, according to the age at onset, here we review the more frequently observed paediatric electro-clinical syndrome from their clinical-EEG, genetic and therapeutic point of views.

Citing Articles

A Temporospatial Study of Sympathetic Skin Response and Electroencephalogram in Oral Mucosa Thermal Perception.

Zhang H, Hu S, Wang Z, Li X, Wang S, Chen G Front Neurosci. 2022; 16:907658.

PMID: 35911991 PMC: 9337692. DOI: 10.3389/fnins.2022.907658.


Risk Factors for Drug Resistance in Epileptic Children with Age of Onset above Five Years: A Case-Control Study.

Mangunatmadja I, Indra R, Widodo D, Rafli A Behav Neurol. 2021; 2021:9092824.

PMID: 34804259 PMC: 8598367. DOI: 10.1155/2021/9092824.


Computational modeling of epilepsy for an experimental neurologist.

Holt A, Netoff T Exp Neurol. 2012; 244:75-86.

PMID: 22617489 PMC: 3769176. DOI: 10.1016/j.expneurol.2012.05.003.

References
1.
Gallagher S, Weiss S, Oram Cardy J, Humphries T, Harman K, Menascu S . Efficacy of very high dose steroid treatment in a case of Landau-Kleffner syndrome. Dev Med Child Neurol. 2006; 48(9):766-9. DOI: 10.1017/S0012162206001630. View

2.
Fejerman N, Cersosimo R, Caraballo R, Grippo J, Corral S, Martino R . Vigabatrin as a first-choice drug in the treatment of West syndrome. J Child Neurol. 2000; 15(3):161-5. DOI: 10.1177/088307380001500304. View

3.
Deonna T, Roulet E . Autistic spectrum disorder: evaluating a possible contributing or causal role of epilepsy. Epilepsia. 2006; 47 Suppl 2:79-82. DOI: 10.1111/j.1528-1167.2006.00697.x. View

4.
Porter R, Partiot A, Sachdeo R, Nohria V, Alves W . Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007; 68(15):1197-204. DOI: 10.1212/01.wnl.0000259034.45049.00. View

5.
Royer-Zemmour B, Ponsole-Lenfant M, Gara H, Roll P, Leveque C, Massacrier A . Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. Hum Mol Genet. 2008; 17(23):3617-30. DOI: 10.1093/hmg/ddn256. View